Persistent endothelial activation in the setting of COVID-19 is associated with increased levels of von Willebrand factor (vWF) and soluble thrombomodulin, which lead to a loss of venous compliance and increased venous congestion [80]. The gene discussed is VWF; the disease is COVID-19.